Compare Eli Lilly And Co (LLY) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Main Street Capital Corporation — how do they compare? Eli Lilly And Co trades at $1,176.52 (market cap $1.04T), while Main Street Capital Corporation trades at $53.86 (market cap $5.09B). The key difference: Eli Lilly And Co is far larger — about 204.3× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (5.84%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Main Street Capital Corporation for 89 Days on average.
| LLY | MAIN | |
|---|---|---|
Market Cap | $1.04T | $5.09B |
Volume | 3,064,878 | 524,060 |
Sector | Health | Financials |
52-Week High | $1.28K | $64.60 |
52-Week Low | $799.57 | $49.63 |
Typical Hold Time | 93 Days | 89 Days |
Enterprise Value | $1.09T | $7.54B |
Dividend Yield | 0.59% | 5.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
MAIN trades at $54.15, down slightly over the past day. The stock shows mixed technical signals with a bearish overall trend but oversold short-term RSI. Fundamentally, the company maintains strong profitability with an 80.77% net margin and a P/E of 10.94, though revenue is expected to decline in 2026. Recent earnings have been mixed with a beat in Q2 2026 but a miss in Q1 2026.
The outlook is cautious. Analyst consensus is a Hold with a $58.33 price target, implying modest upside. Risks include softening earnings and negative operating cash flow. The dividend remains well-covered, supporting income investors, but growth prospects appear limited near-term amid a bearish technical setup.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
